Christopher F. Mojcik

5.3k total citations · 2 hit papers
35 papers, 3.6k citations indexed

About

Christopher F. Mojcik is a scholar working on Immunology, Rheumatology and Hematology. According to data from OpenAlex, Christopher F. Mojcik has authored 35 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Immunology, 9 papers in Rheumatology and 8 papers in Hematology. Recurrent topics in Christopher F. Mojcik's work include Complement system in diseases (8 papers), Systemic Lupus Erythematosus Research (7 papers) and T-cell and B-cell Immunology (7 papers). Christopher F. Mojcik is often cited by papers focused on Complement system in diseases (8 papers), Systemic Lupus Erythematosus Research (7 papers) and T-cell and B-cell Immunology (7 papers). Christopher F. Mojcik collaborates with scholars based in United States, United Kingdom and Netherlands. Christopher F. Mojcik's co-authors include Russell P. Rother, Scott A. Rollins, Robert A. Brodsky, Leonard Bell, Peter Hillmen, Ethan M. Shevach, Modupe Elebute, Anita Hill, Judith Marsh and Stephen J. Richards and has published in prestigious journals such as New England Journal of Medicine, JAMA and Circulation.

In The Last Decade

Christopher F. Mojcik

35 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

2006 878 citations Peter Hillmen, Neal S. Young et al. New England Journal of Medicine profile →
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

2007 570 citations Russell P. Rother, Scott A. Rollins et al. Nature Biotechnology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher F. Mojcik United States	21	2.2k	991	906	520	441	35	3.6k
Anita Hill United Kingdom	23	2.7k 1.2×	1.4k 1.4×	2.2k 2.4×	1.2k 2.3×	97 0.2×	54	4.2k
Marie‐Agnès Dragon‐Durey France	39	4.8k 2.2×	3.3k 3.4×	2.3k 2.5×	742 1.4×	523 1.2×	100	5.7k
X. Long Zheng United States	43	3.8k 1.7×	1.4k 1.4×	3.2k 3.5×	1.5k 3.0×	69 0.2×	181	5.9k
David Hagerty United States	19	1.6k 0.7×	221 0.2×	627 0.7×	340 0.7×	1.3k 3.0×	34	4.2k
Kenneth H. Shumak Canada	16	1.9k 0.9×	978 1.0×	1.2k 1.3×	600 1.2×	79 0.2×	30	2.7k
Leticia Nolasco United States	25	2.2k 1.0×	707 0.7×	2.4k 2.7×	653 1.3×	33 0.1×	38	3.7k
Patricia Redecha United States	27	2.2k 1.0×	486 0.5×	1.0k 1.1×	283 0.5×	1.6k 3.6×	43	4.3k
Hermine Agis Austria	32	1.9k 0.8×	111 0.1×	875 1.0×	567 1.1×	592 1.3×	123	3.2k
Jennifer H. Anolik United States	41	3.7k 1.7×	290 0.3×	437 0.5×	843 1.6×	2.5k 5.6×	89	6.1k
Marten Trendelenburg Switzerland	29	1.6k 0.7×	571 0.6×	280 0.3×	174 0.3×	1.2k 2.8×	129	2.5k

Countries citing papers authored by Christopher F. Mojcik

Since Specialization

Citations

This map shows the geographic impact of Christopher F. Mojcik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher F. Mojcik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher F. Mojcik more than expected).

Fields of papers citing papers by Christopher F. Mojcik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher F. Mojcik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher F. Mojcik. The network helps show where Christopher F. Mojcik may publish in the future.

Co-authorship network of co-authors of Christopher F. Mojcik

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher F. Mojcik. A scholar is included among the top collaborators of Christopher F. Mojcik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher F. Mojcik. Christopher F. Mojcik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Weinhold, Kent J., Jack F. Bukowski, Todd V. Brennan, et al.. (2018). Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers. Clinical Immunology. 191. 10–20. 26 indexed citations

Rother, Russell P., Scott A. Rollins, Christopher F. Mojcik, Robert A. Brodsky, & Leonard Bell. (2007). Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nature Biotechnology. 25(11). 1256–1264. 570 indexed citations breakdown →

Hillmen, Peter, Neal S. Young, Jörg Schubert, et al.. (2006). The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. New England Journal of Medicine. 355(12). 1233–1243. 878 indexed citations breakdown →

Goyal, Abhinav, Kenneth W. Mahaffey, Jyotsna Garg, et al.. (2006). Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study. European Heart Journal. 27(11). 1289–1297. 135 indexed citations

Hill, Anita, Peter Hillmen, Stephen J. Richards, et al.. (2005). Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood. 106(7). 2559–2565. 165 indexed citations

Buckland‐Wright, J. C., R.J. Ward, Charles Peterfy, Christopher F. Mojcik, & Richard L. Leff. (2004). Reproducibility of the semiflexed (metatarsophalangeal) radiographic knee position and automated measurements of medial tibiofemoral joint space width in a multicenter clinical trial of knee osteoarthritis.. PubMed. 31(8). 1588–97. 60 indexed citations

Werf, Frans Van de, Paul W. Armstrong, Jerrold H. Levy, et al.. (2004). 810-4 Pexelizumab, a C5 complement inhibitor, reduces 30-day mortality in patients undergoing coronary artery bypass surgery or receiving reperfusion therapy for acute myocardial infarction. Journal of the American College of Cardiology. 43(5). A474–A474. 1 indexed citations

Verrier, Edward D., Stanton K. Shernan, Kenneth M. Taylor, et al.. (2004). Terminal Complement Blockade With Pexelizumab During Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass. JAMA. 291(19). 2319–2319. 138 indexed citations

Hillmen, Peter, Claire Hall, Judith Marsh, et al.. (2004). Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria. New England Journal of Medicine. 350(6). 552–559. 452 indexed citations

10.

Mojcik, Christopher F., et al.. (2001). Aprotinin and the systemic inflammatory response after cardiopulmonary bypass. The Annals of Thoracic Surgery. 71(2). 745–754. 153 indexed citations

11.

Salomon, Daniel R., Laura Crisá, Christopher F. Mojcik, et al.. (1997). Vascular Cell Adhesion Molecule-1 Is Expressed by Cortical Thymic Epithelial Cells and Mediates Thymocyte Adhesion. Implications for the Function of α4β1 (VLA4) Integrin in T-Cell Development. Blood. 89(7). 2461–2471. 60 indexed citations

12.

Mojcik, Christopher F. & Ethan M. Shevach. (1997). Adhesion molecules. A rheumatologic perspective. Arthritis & Rheumatism. 40(6). 991–1004. 120 indexed citations

13.

Mojcik, Christopher F., et al.. (1996). End-stage renal disease and systemic lupus erythematosus. The American Journal of Medicine. 101(1). 100–107. 107 indexed citations

14.

Chang, Andrew C., Daniel R. Salomon, Sarah Wadsworth, et al.. (1995). Alpha 3 beta 1 and alpha 6 beta 1 integrins mediate laminin/merosin binding and function as costimulatory molecules for human thymocyte proliferation.. The Journal of Immunology. 154(2). 500–510. 56 indexed citations

15.

Salomon, Daniel R., Christopher F. Mojcik, Andrew C. Chang, et al.. (1994). Constitutive activation of integrin alpha 4 beta 1 defines a unique stage of human thymocyte development.. The Journal of Experimental Medicine. 179(5). 1573–1584. 74 indexed citations

16.

Mojcik, Christopher F., Mark F. Gourley, Dennis M. Klinman, et al.. (1993). Administration of a Phosphorothioate Oligonucleotide Antisense to Murine Endogenous Retroviral MCF env Causes Immune Effects in Vivo in a Sequence-Specific Manner. Clinical Immunology and Immunopathology. 67(2). 130–136. 30 indexed citations

17.

Gourley, Mark F., et al.. (1992). Molecular Aspects of Systemic Lupus Erythematosus: Murine Endogenous Retroviral Expression. DNA and Cell Biology. 11(3). 253–257. 8 indexed citations

18.

Mojcik, Christopher F., Dale L. Greiner, & Irving Goldschneider. (1990). Characterization of RT6‐Bearing Rat Lymphocytes. II. Developmental Relationships of RT6‐ and RT6+T Cells. Journal of Immunology Research. 1(3). 191–201. 17 indexed citations

19.

Mojcik, Christopher F., Dale L. Greiner, Eugene S. Medlock, Kristin L. Komschlies, & Irving Goldschneider. (1988). Characterization of RT6 bearing rat lymphocytes. Cellular Immunology. 114(2). 336–346. 43 indexed citations

20.

Braciale, Thomas J., Christopher F. Mojcik, & Věra Hauptfeld. (1982). Target-cell recognition by cloned lines of influenza virus-specific cytotoxic T lymphocytes. Selective inhibition by a monoclonal H-2-specific antibody. Immunogenetics. 15(1). 41–52. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact